Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study

We assessed the virologic efficacy of switching to co-formulated elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (E/C/F/TDF) in patients with controlled HIV infection. We conducted a retrospective multicenter observational cohort study including adult patients with controlled...

Full description

Saved in:
Bibliographic Details
Published in:AIDS research and therapy 2023-01, Vol.20 (1), p.1-10, Article 1
Main Authors: De Castro, Nathalie, Brun, Alexandre, Sellier, Pierre, Hamet, Gwenn, Mechaï, Frédéric, Garrait, Valérie, Chabrol, Amélie, Bouldouyre, Marie-Anne, Froguel, Eric, Troisvallets, Didier, Caraux-Paz, Pauline, Delaugerre, Constance, Rozenbaum, Willy, Molina, Jean-Michel
Format: Article
Language:English
Subjects:
Adult
Algorithms
Analysis
Anti-HIV agents
Anti-HIV Agents - adverse effects
Antiviral agents
Biological products industry
Cobicistat - adverse effects
Cobicistat - therapeutic use
Cohort Studies
Control
Dosage and administration
Drug therapy
E/C/F/TDF
Emtricitabine - adverse effects
Emtricitabine - therapeutic use
Female
Health aspects
HIV (Viruses)
HIV infection
HIV Infections - drug therapy
HIV patients
Humans
Infection
Infection control
Integrase Inhibitors - therapeutic use
integrase resistance
Male
Medical research
Medicine, Experimental
RNA
switch
Tenofovir - adverse effects
Tenofovir - therapeutic use
Testing
virologic efficacy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We assessed the virologic efficacy of switching to co-formulated elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (E/C/F/TDF) in patients with controlled HIV infection. We conducted a retrospective multicenter observational cohort study including adult patients with controlled HIV-1 infection on any stable antiretroviral (ART) regimen, who switched to E/C/F/TDF. Success was measured by the proportion of patients with plasma viral load 
ISSN:1742-6405
1742-6405
DOI:10.1186/s12981-022-00499-4